Sumatriptan succinate (Zembrace SymTouch) vs Sumatriptan (Tosymra)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline

Sumatriptan succinate (Zembrace SymTouch)

Marketed by Tonix Pharmaceuticals and partners

Approved in Migrainesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Sumatriptan (Tosymra)

Marketed by Tonix Pharmaceuticals and partners

Approved in Migrainesmall molecule
Weak signal

NCT02279082 · Phase 3 · completed

This was a single-arm, open-label study of 167 participants with no randomization, blinding, or comparator arm. Its primary endpoint was the number of participants with treatment-emergent adverse events, reported in 120 participants over six months, so the study provides descriptive safety information but cannot establish comparative safety or treatment efficacy.

Reported efficacy

Number of Participants With Treatment Emergent Adverse Events (6 months): Number of Participants With Treatment Emergent Adverse Events (6 months): DFN-02 120 Participants (not_applicable)

Result source: NCT02279082

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Sumatriptan succinate (Zembrace SymTouch): registry results are on file for Migraine, but their comparison mappings are not yet available.

Sumatriptan (Tosymra): registry results are on file for Migraine, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sumatriptan succinate (Zembrace SymTouch)'s landscape · Sumatriptan (Tosymra)'s landscape